The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InDaVita (DVA) shares surged 20% to a new all-time high after reporting a non-GAAP EPS of $2.87, significantly beating consensus estimates. The company's operational strength was highlighted by a first-quarter revenue of $3.5 billion and an expanded adjusted operating margin of 19.1%. Following these results, Barclays analyst Andrew Mok raised the price target for DVA to $194.00 from $158.00. Furthermore, DaVita raised its full-year 2026 adjusted EPS forecast to a specific range of $14.10 to $15.20, reinforcing its mid-teens growth trajectory. This outlook is underpinned by a robust free cash flow yield exceeding 10%, signaling strong capital efficiency. Analysts believe these updated metrics and specific long-term targets underscore the company's strategic resilience and dominant position in the healthcare sector.